{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-002090","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2022-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.418659+00:00","generated_at":"2026-06-27T04:01:50.780590+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Zivo Bioscience terminates CEO Andrew Dahl for cause; Dahl resigns from board","bullets":["CEO Andrew A. Dahl terminated for cause on Jan 4, 2022 after declining to resign; no separation agreement reached.","On Feb 18, 2022, Dahl resigned from the board of directors; board size reduced to four members.","Principal executive office moved to 21 E. Long Lake Road, Suite 100, Bloomfield Hills, MI effective Feb 21, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-002090","json":"https://secwatch.observer/filing/0001654954-22-002090.json","markdown":"https://secwatch.observer/filing/0001654954-22-002090.md","text":"https://secwatch.observer/filing/0001654954-22-002090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/0001654954-22-002090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:01:50.780590+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be54acfe23","claim":"Andrew A. Dahl resigned as member of the board of directors at Zivo Bioscience, Inc..","evidence_excerpt":"on February 18, 2022, Mr. Dahl resigned from his position as a member of the Company’s board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/0001654954-22-002090-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"member of the board of directors"}],"fact_type":"executive_change"},{"claim_id":"e71f74bf37","claim":"Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..","evidence_excerpt":"the Company terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422002090/0001654954-22-002090-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}